Prolonged time to progression with fulvestrant for metastatic breast cancer.
Mello
Celso A L
CA
Fundação Antônio Prudente, Hospital do Câncer A. C. Camargo, Rua Prof Antônio Prudente, Liberdade, São Paulo, SP, 01509-900, Brazil. celso.mello@hcancer.org.br
Chinen
Ludmilla T D
LT
da Silva
Samantha Cabral Severino
SC
do Nascimento Matias
Carolina
C
Benevides
Carlos Frederico
CF
Gimenes
Daniel Luiz
DL
Fanelli
Marcello F
MF
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015331:Cohort Studies; D018450:Disease Progression; D018572:Disease-Free Survival; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D018734:Genes, erbB-2; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D011960:Receptors, Estrogen / Q000096:biosynthesis / Q000235:genetics; D011980:Receptors, Progesterone / Q000096:biosynthesis / Q000235:genetics; D012189:Retrospective Studies
D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000077267:Fulvestrant; D004958:Estradiol